| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Janusz Rybakowsk. Sixty years of recurrence prevention in mood disorders. Psychiatria polska. vol 58. issue 2. 2024-07-14. PMID:39003507. |
since the mid-1990s, 2nd generation of mood-stabilizing drugs has been introduced, including some atypical antipsychotics (clozapine, olanzapine, quetiapine, aripiprazole, risperidone) and anticonvulsant drug, lamotrigine, showing prophylactic activity in bipolar mood disorder. |
2024-07-14 |
2024-07-16 |
Not clear |
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. |
it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. |
2024-02-10 |
2024-02-12 |
Not clear |
| Ayman M Al-Qaaneh, Osama S Al-Mohammadi, Razan A Musharraf, Jumanah S AlSaedi, Jana L Shaker, Ahmed J Aldhafir. Prescription patterns of quetiapine for multiple drug abuse, depression, and psychosis: A retrospective study. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. vol 31. issue 12. 2023-11-14. PMID:37961072. |
quetiapine is an atypical antipsychotic prescribed for schizophrenia, bipolar disorder, multiple drug abuse (mda), generalized anxiety disorder, severe depression, dementia, and mood disorders. |
2023-11-14 |
2023-11-20 |
Not clear |
| Calogero Crapanzano, Stefano Damiani, Cecilia Guio. Quetiapine in the Anxiety Dimension of Mood Disorders: A Systematic Review of the Literature to Support Clinical Practice. Journal of clinical psychopharmacology. vol 41. issue 4. 2021-06-29. PMID:34166261. |
quetiapine in the anxiety dimension of mood disorders: a systematic review of the literature to support clinical practice. |
2021-06-29 |
2023-08-13 |
Not clear |
| Calogero Crapanzano, Stefano Damiani, Cecilia Guio. Quetiapine in the Anxiety Dimension of Mood Disorders: A Systematic Review of the Literature to Support Clinical Practice. Journal of clinical psychopharmacology. vol 41. issue 4. 2021-06-29. PMID:34166261. |
this study examines current knowledge to evaluate the efficacy of quetiapine in the treatment of anxiety in mood disorders. |
2021-06-29 |
2023-08-13 |
Not clear |
| Laura Albantakis, Karin Egberts, Rainer Burger, Christine Kulpok, Claudia Mehler-Wex, Regina Taurines, Stefan Unterecker, Christoph Wewetzer, Marcel Romanos, Manfred Gerlac. Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders. Pharmacopsychiatry. vol 50. issue 6. 2018-08-14. PMID:28561203. |
relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders. |
2018-08-14 |
2023-08-13 |
Not clear |
| Claudia Cornelis, Ann Van Gastel, Glenn Dumont, Violette Coppens, Bernard Sabbe, Manuel Morrens, Filip Van Den Eed. A case of dose escalation of quetiapine in persistent insomnia disorder. Acta clinica Belgica. vol 72. issue 5. 2018-06-06. PMID:27960654. |
quetiapine, an atypical antipsychotic drug, is recommended for the treatment of schizophrenia and mood disorders. |
2018-06-06 |
2023-08-13 |
Not clear |
| Francisco López-Muñoz, Cecilio Alam. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Frontiers in psychiatry. vol 4. 2014-06-24. PMID:24062697. |
active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. |
2014-06-24 |
2023-08-12 |
Not clear |
| Jacqueline Frayne, Thinh Nguyen, Rolland Kohan, Nick De Felice, Jonathan Rampon. The comprehensive management of pregnant women with major mood disorders: a case study involving phenelzine, lithium, and quetiapine. Archives of women's mental health. vol 17. issue 1. 2014-03-24. PMID:24196828. |
the comprehensive management of pregnant women with major mood disorders: a case study involving phenelzine, lithium, and quetiapine. |
2014-03-24 |
2023-08-12 |
Not clear |
| Bernardo Dell'Osso, Chiara Arici, Cristina Dobrea, Beatrice Benatti, A Carlo Altamur. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. International clinical psychopharmacology. vol 27. issue 6. 2013-07-10. PMID:22990141. |
the present study aimed to assess switch from immediate-release (ir) to extended-release (xr) quetiapine in terms of efficacy, tolerability, compliance, and quality of life in a sample of patients with mood disorders. |
2013-07-10 |
2023-08-12 |
Not clear |
| Bernardo Dell'Osso, Chiara Arici, Cristina Dobrea, Beatrice Benatti, A Carlo Altamur. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. International clinical psychopharmacology. vol 27. issue 6. 2013-07-10. PMID:22990141. |
efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. |
2013-07-10 |
2023-08-12 |
Not clear |
| Yi-Chih Chen, Chih-Ken Chen, Liang-Jen Wan. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC psychiatry. vol 12. 2013-05-31. PMID:23020711. |
this pilot study evaluated the feasibility of extended-release quetiapine fumarate (quetiapine xr) for the treatment of patients with either a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms compared to a placebo, as an adjunct to antidepressant therapy. |
2013-05-31 |
2023-08-12 |
Not clear |
| Yi-Chih Chen, Chih-Ken Chen, Liang-Jen Wan. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC psychiatry. vol 12. 2013-05-31. PMID:23020711. |
quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. |
2013-05-31 |
2023-08-12 |
Not clear |
| Hua Jin, Pei-an Betty Shih, Shahrokh Golshan, Sunder Mudaliar, Robert Henry, Danielle K Glorioso, Stephan Arndt, Helena C Kraemer, Dilip V Jest. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. The Journal of clinical psychiatry. vol 74. issue 1. 2013-04-15. PMID:23218100. |
to compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using dsm-iv-tr criteria. |
2013-04-15 |
2023-08-12 |
Not clear |
| Ku Chui Yong, Tan Aik Kah, Yeap Thye Ghee, Lim Chee Siang, Mae-Lynn Catherine Bastio. Branch retinal vein occlusion associated with quetiapine fumarate. BMC ophthalmology. vol 11. 2012-01-03. PMID:21867521. |
to report a case of branch retinal vein occlusion in a young adult with bipolar mood disorder treated with quetiapine fumarate. |
2012-01-03 |
2023-08-12 |
Not clear |
| Bernhard T Baun. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatric disease and treatment. vol 4. issue 6. 2011-05-18. PMID:19337458. |
quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. |
2011-05-18 |
2023-08-12 |
Not clear |
| P Shajahan, M Taylo. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. Journal of psychopharmacology (Oxford, England). vol 24. issue 4. 2010-06-18. PMID:19164493. |
we conducted an electronic chart review of a sample of all people attending secondary mental health care, in the county of lanarkshire, scotland, who were commenced on quetiapine for the following mood disorders: non-psychotic depression (n = 171), psychotic depression (n = 39), bipolar mania (n = 24), bipolar depression (n = 38) and bipolar mixed states (n = 31), between 2002 and 2007. |
2010-06-18 |
2023-08-12 |
Not clear |
| P Shajahan, M Taylo. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. Journal of psychopharmacology (Oxford, England). vol 24. issue 4. 2010-06-18. PMID:19164493. |
the uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. |
2010-06-18 |
2023-08-12 |
Not clear |
| Satoshi Yamamura, Keiko Ohoyama, Tatsuya Hamaguchi, Kanae Kashimoto, Masanori Nakagawa, Shinichi Kanehara, Dai Suzuki, Takuya Matsumoto, Eishi Motomura, Takashi Shiroyama, Motohiro Okad. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology. vol 206. issue 2. 2009-12-22. PMID:19575183. |
the atypical antipsychotic drug, quetiapine (qtp), is effective in schizophrenia and mood disorders, but induces seizures compared to typical antipsychotics. |
2009-12-22 |
2023-08-12 |
rat |
| Helen R Winter, Willie R Earley, Jennifer E Hamer-Maansson, Patty C Davis, Mark A Smit. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Journal of child and adolescent psychopharmacology. vol 18. issue 1. 2008-05-13. PMID:18294091. |
the aim of this study was to investigate the steady-state pharmacokinetic, safety, and tolerability profiles of immediate-release quetiapine administered by similar dose-escalation regimens in pediatric and adult populations with psychotic or mood disorders. |
2008-05-13 |
2023-08-12 |
Not clear |